CN115068685A - Platelet-rich fibrin composite membrane and preparation method and application thereof - Google Patents
Platelet-rich fibrin composite membrane and preparation method and application thereof Download PDFInfo
- Publication number
- CN115068685A CN115068685A CN202210773569.6A CN202210773569A CN115068685A CN 115068685 A CN115068685 A CN 115068685A CN 202210773569 A CN202210773569 A CN 202210773569A CN 115068685 A CN115068685 A CN 115068685A
- Authority
- CN
- China
- Prior art keywords
- platelet
- fat
- rich fibrin
- composite membrane
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims abstract description 74
- 102000009123 Fibrin Human genes 0.000 title claims abstract description 73
- 108010073385 Fibrin Proteins 0.000 title claims abstract description 73
- 229950003499 fibrin Drugs 0.000 title claims abstract description 73
- 239000012528 membrane Substances 0.000 title claims abstract description 59
- 239000002131 composite material Substances 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 15
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 15
- 208000008960 Diabetic foot Diseases 0.000 claims abstract description 12
- 229920001661 Chitosan Polymers 0.000 claims abstract description 9
- 238000004132 cross linking Methods 0.000 claims abstract description 4
- 239000002245 particle Substances 0.000 claims description 33
- 210000004369 blood Anatomy 0.000 claims description 25
- 239000008280 blood Substances 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 23
- 206010052428 Wound Diseases 0.000 claims description 22
- 208000027418 Wounds and injury Diseases 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 19
- 239000011259 mixed solution Substances 0.000 claims description 15
- 230000008961 swelling Effects 0.000 claims description 14
- 235000006708 antioxidants Nutrition 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 206010002091 Anaesthesia Diseases 0.000 claims description 8
- 230000037005 anaesthesia Effects 0.000 claims description 8
- 239000003146 anticoagulant agent Substances 0.000 claims description 8
- 229940127219 anticoagulant drug Drugs 0.000 claims description 8
- 208000032912 Local swelling Diseases 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 210000002808 connective tissue Anatomy 0.000 claims description 7
- 238000005520 cutting process Methods 0.000 claims description 7
- 230000001804 emulsifying effect Effects 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000002960 lipid emulsion Substances 0.000 claims description 7
- 238000007443 liposuction Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 6
- 239000001263 FEMA 3042 Substances 0.000 claims description 6
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 6
- 210000001015 abdomen Anatomy 0.000 claims description 6
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 claims description 6
- 235000015523 tannic acid Nutrition 0.000 claims description 6
- 229920002258 tannic acid Polymers 0.000 claims description 6
- 229940033123 tannic acid Drugs 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 3
- 235000021283 resveratrol Nutrition 0.000 claims description 3
- 229940016667 resveratrol Drugs 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- FENRSEGZMITUEF-ATTCVCFYSA-E [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] FENRSEGZMITUEF-ATTCVCFYSA-E 0.000 claims description 2
- 229960003638 dopamine Drugs 0.000 claims description 2
- 235000004515 gallic acid Nutrition 0.000 claims description 2
- 229940074391 gallic acid Drugs 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 229940083982 sodium phytate Drugs 0.000 claims description 2
- 230000017423 tissue regeneration Effects 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 claims 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 claims 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 claims 1
- 229940026509 theaflavin Drugs 0.000 claims 1
- 235000014620 theaflavin Nutrition 0.000 claims 1
- 239000003102 growth factor Substances 0.000 abstract description 13
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract description 7
- 239000001110 calcium chloride Substances 0.000 abstract description 7
- 229910001628 calcium chloride Inorganic materials 0.000 abstract description 7
- 235000011148 calcium chloride Nutrition 0.000 abstract description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 abstract description 5
- 239000001301 oxygen Substances 0.000 abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 2
- 230000002000 scavenging effect Effects 0.000 abstract description 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000010902 straw Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 230000035876 healing Effects 0.000 description 4
- 238000002690 local anesthesia Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 238000002639 hyperbaric oxygen therapy Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001045 maggot therapy Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- -1 uniform platelets Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/046—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L31/129—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a platelet-rich fibrin composite membrane and a preparation method and application thereof, wherein the platelet-rich fibrin composite membrane is a nano-fat combined platelet-rich fibrin composite membrane, and the nano-fat combined platelet-rich fibrin composite membrane is prepared from autologous nano-fat, platelet-rich fibrin, quaternized chitosan and medical CaCl 2 The solution and the antioxidant are prepared by ionic crosslinking. The invention belongs to the field of biomedical materials, and provides a nano-fat combined platelet-rich fibrin composite membrane prepared from autologous nano-fat, PRF, QCS, medical CaCl2 solution and an antioxidant. The composite membrane provided by the invention not only can continuously release growth factors on the wound surface of the diabetic foot, but also has good mechanical properties, antibacterial and anti-inflammatory properties, active oxygen scavenging and controllable degradation capability.
Description
Technical Field
The invention belongs to the field of biomedical materials, and particularly relates to a platelet-rich fibrin composite membrane, a preparation method and application thereof, more specifically to application of the platelet-rich fibrin composite membrane to a diabetic foot wound.
Background
The treatment cost of the diabetic foot wound is high and the time consumption is long, so that great burden is caused to a patient, and simultaneously great challenge is brought to a medical system. At present, the methods for treating diabetic foot wounds comprise growth factors, negative pressure wound drainage, ultrasonic therapy, maggot therapy, phototherapy, local debridement treatment, artificial skin substitutes and hyperbaric oxygen therapy, and the treatment effect is improved; however, most patients still have amputation due to the limitation of treatment methods, so that the labor capacity and the self-care ability of life are lost, and the life quality of the patients is greatly reduced. Thus, the clinician's focus in treating diabetic feet is shifting from passive therapy to early intervention and active exploration of more rational treatment regimens.
The diabetic foot wound is difficult to heal because the growth factor at the wound has low content and poor activity, so that characteristic cells cannot be effectively activated and repaired, the proliferation, differentiation and migration of the cells are hindered, the granulation tissue formation and the wound microcirculation reconstruction are inhibited, and the normal healing process of the wound is interrupted. The platelet-rich fibrin (PRF) is a platelet concentrate prepared by centrifuging autologous blood at a low speed and a long time, contains uniformly distributed and wide-range growth factors, has strong antibacterial and anti-inflammatory capabilities and potential for promoting wound tissue healing and regeneration, and is considered to be one of the most promising methods for treating diabetic foot wounds. However, Platelet Rich Fibrin (PRF) also has significant drawbacks: on one hand, the blood needs to be taken for many times, and the blood is prepared on the spot when in use, so that serious psychological disorder is caused to a patient; on the other hand, the platelet-rich fibrin (PRF) gel has the problems of short action time of growth factors, easy loss and the like, and the two points limit the clinical application of the platelet-rich fibrin gel to a certain extent.
Disclosure of Invention
Aiming at the situation, aiming at solving the problems that the platelet-rich fibrin (PRF) has multiple blood sampling, the existing preparation and the short action time and easy loss of the growth factor in the traditional platelet-rich fibrin (PRF) gel when the platelet-rich fibrin (PRF) is used for treating diabetic foot wounds, the invention provides a platelet-rich fibrin composite membrane and a preparation method and application thereof, wherein the platelet-rich fibrin composite membrane adopted in the invention is a nano fat combined platelet-rich fibrin composite membrane, the preparation method of the nano fat combined platelet-rich fibrin composite membrane is simple, the nano fat combined platelet-rich fibrin composite membrane can be stored for a long time under mild conditions, the psychological loss of patients caused by multiple blood sampling and existing preparation is avoided, and the prepared platelet-rich fibrin composite membrane has a loose fibrin structure, high content of platelets, leukocytes and growth factors, and is uniform and wide in distribution; and secondly, the foot wound surface protecting agent has strong antibacterial and anti-inflammatory capabilities and active oxygen removing capability, and further solves the problems of growth factor deficiency, growth factor activity reduction and the like caused by susceptibility and excessive active oxygen at the foot wound surface of the diabetic.
The invention provides the following technical scheme: the platelet-rich fibrin composite membrane is a nano-fat combined platelet-rich fibrin composite membrane, and is prepared from autologous nano-fat, platelet-rich fibrin (PRF), Quaternized Chitosan (QCS) and medical CaCl 2 The solution and the antioxidant are prepared by ion crosslinking.
Further, the nano-meterThe volume ratio of the raw materials of the formula of the fat-combined platelet-rich fibrin composite membrane is as follows: the volume ratio of the platelet-rich fibrin (PRF) to the autologous nano fat is 1: 5-1: 3, the volume ratio of the platelet-rich fibrin (PRF) to the Quaternized Chitosan (QCS) is 1: 5-1: 1, the volume ratio of the platelet-rich fibrin (PRF) to the antioxidant is 1: 3-1: 1, and medical CaCl is added into each milliliter of the platelet-rich fibrin (PRF) 2 The amount of the solution is 200-500. mu.L/mL.
Further, the mass fraction of the Quaternized Chitosan (QCS) is 2-6%.
Further, the antioxidant is selected from one or a mixture of more than two of gallic acid, tannic acid, tea yellow pigment, dopamine, resveratrol, sodium phytate and vitamin C.
Further, the mass fraction of the antioxidant is 1-4%.
The invention provides a preparation method of a platelet-rich fibrin composite membrane, which specifically comprises the following steps:
s1, mixing the autologous nano fat and the platelet-rich fibrin (PRF) uniformly according to the volume ratio of the raw materials of the formula, and placing the mixture at 4 ℃ for later use;
s2, quaternizing the chitosan (QCS), the antioxidant and the medical CaCl under the normal temperature condition 2 The solution is stirred in proportion to form uniform mixed solution;
s3, stirring the mixture obtained in the step S1 and the mixed solution obtained in the step S2 uniformly at 4 ℃, transferring the mixture to a culture dish, and standing to form a membrane.
Further, the preparation method of the autologous nano-fat in step S1 is as follows:
(1) performing local swelling anesthesia around the navel of the abdomen of a patient, connecting a 20mL syringe with a liposuction needle with the aperture of 1mm, and performing radial suction under the condition of artificial negative pressure to obtain about 100mL of tiny granular fat;
(2) standing the injector for 10-15min, obviously layering the tiny fat particles and the swelling solution, removing the swelling solution, and washing the tiny fat particles with normal saline for 2-3 times;
(3) distributing the tiny particle fat in the step (2) into a 20mL injector, centrifuging for 3min at the rotating speed of 2000-3000rpm/min, removing water, and collecting the tiny particle fat;
(4) subpackaging the micro-particle fat collected in the step (3) in a 20mL syringe, connecting with a nano fat converter, continuously and mechanically cutting for 10-20 times, mechanically emulsifying, and continuously oscillating the emulsified fat for 1-2min under the condition of artificial negative pressure;
(5) centrifuging at the rotating speed of 2000-;
(6) filtering the emulsified fat with a filter screen with pore diameter of 0.5mm for 2-3 times, and removing the residual connective tissue to obtain fat emulsion, namely the autologous nano fat.
Further, the Platelet Rich Fibrin (PRF) is prepared in step S1 as follows:
(1) collecting 100mL of venous blood of a patient, and putting the collected blood into a centrifuge tube without anticoagulant;
(2) immediately centrifuging at the rotating speed of 1000-1600 rpm/min for 10-20min, and taking the middle gel layer to obtain platelet-rich fibrin (PRF);
(3) the obtained platelet-rich fibrin (PRF) is stored at 4 ℃ for further use.
The invention provides an application of a platelet-rich fibrin composite membrane, in particular to an application of a nano-fat and platelet-rich fibrin composite membrane in diabetic foot wound surfaces, tooth tissue regeneration membranes and artificial skin.
The invention with the structure has the following beneficial effects: compared with the prior art, the platelet-rich fibrin composite membrane and the preparation method and the application thereof provided by the invention have the following advantages:
(1) the nano-fat and platelet-rich fibrin composite membrane provided by the invention adopts autologous nano-fat, PRF, QCS and antioxidant to carry out ionic crosslinking through CaCl2 solution, and the components are synergistic with each other, so that the mechanical property of the composite membrane is improved, and a protective barrier is provided for the wound surface.
(2) The components such as QCS, antioxidant and the like in the nano-fat combined platelet-rich fibrin composite membrane provided by the invention can inhibit bacterial reproduction and remove active oxygen at the wound surface of diabetic foot, and provide a good healing environment for the wound surface.
(3) The autologous nano fat in the nano fat combined platelet-rich fibrin composite membrane provided by the invention is combined with PRF, so that the immunological rejection is reduced; the composite membrane contains main active ingredients such as uniform platelets, growth factors and leukocytes in the wound healing process, can provide the wound with the growth factors with strong activity, multiple types and high concentration, and the growth factors synergistically promote collagen synthesis, angiogenesis, tissue remodeling and re-epithelialization through different regeneration mechanisms, shorten the healing time of the wound, and can effectively solve the problems of lack of the growth factors and activity reduction of chronic wounds.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention and not to limit the invention. In the drawings:
FIG. 1 is a platelet-rich fibrin composite membrane, a preparation method thereof and autologous nano-fat prepared by the application thereof, according to the present invention;
FIG. 2 is a process diagram of a platelet-rich fibrin composite membrane, a preparation method thereof and a preparation process of platelet-rich fibrin (PRF) using the same;
FIG. 3 is a diagram showing the usage effect of the platelet-rich fibrin composite membrane, the preparation method thereof and the nano-fat combined platelet-rich fibrin composite membrane prepared by the application thereof.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments; all other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
It should be noted that the terms "front," "back," "left," "right," "upper" and "lower" used in the following description refer to directions in the drawings, and the terms "inner" and "outer" refer to directions toward and away from, respectively, the geometric center of a particular component.
Example 1
1. Preparing autologous nano fat:
(1) local swelling anesthesia is carried out on the abdominal periphery of the navel of the patient;
(2) after the anesthesia takes effect, a liposuction needle with the aperture of 1mm is connected with a 20mL syringe for standby;
(3) performing radial suction under the condition of artificial negative pressure to obtain about 100mL of tiny particle fat;
(4) standing the injector for 15min, obviously layering the tiny fat particles and the swelling solution, removing the swelling solution, washing the tiny fat particles with normal saline for 3 times, and removing blood cells;
(5) subpackaging the tiny particle fat in a 20mL injector, centrifuging at the rotating speed of 2500rpm/min for 3min, obviously layering the fat and the water, and removing the water;
(6) subpackaging the tiny particle fat in a 20mL syringe, connecting with a nano fat converter, continuously and mechanically cutting for 15 times, mechanically emulsifying, and continuously oscillating the emulsified fat for 1min under the condition of artificial negative pressure;
(7) centrifuging at 2500rpm/min for 3min to obviously separate emulsified fat from oil, pouring off oil, sucking residual oil with gauze, and collecting emulsified fat;
(8) filtering emulsified fat with 0.5mm filter screen for 3 times to remove residual connective tissue to obtain fat emulsion as nanometer fat;
preparation of PRF:
(1) collecting 10 mL/10 venous blood of a patient, and putting the collected blood into a centrifuge tube without anticoagulant;
(2) centrifuging at 1400rpm/min for 20min to divide blood into three layers, including upper layer of platelet-poor plasma layer, middle layer of RPF gel layer, and lowest layer of erythrocyte layer;
(3) storing the centrifuge tube in a refrigerator at 4 deg.C for 30min, discarding the supernatant, and sucking the intermediate layer with a sterile straw to obtain PRF;
3. preparing a nano-fat combined platelet-rich fibrin composite membrane:
s1, uniformly mixing 5mL of autologous nano fat with 1mL of PRF according to a proportion, and placing at 4 ℃ for later use;
s2, under the condition of normal temperature, 5mL QCS (mass fraction: 3%), 3mL tannic acid (mass fraction: 2%) and 400 μ L medical CaCl 2 Stirring the solution to form a uniform mixed solution;
s3, stirring the mixture obtained in the step S1 and the mixed solution of S2 uniformly at 4 ℃, transferring the mixture to a culture dish, and standing to form a membrane.
Example 2
1. Preparing autologous nano fat:
(1) local swelling anesthesia is carried out around the navel of the abdomen of the patient;
(2) after local anesthesia takes effect, a liposuction needle with the aperture of 1mm is connected with a 20mL syringe for standby;
(3) performing radial suction under the condition of artificial negative pressure to obtain about 100mL of tiny particle fat;
(4) standing the injector for 15min, obviously layering the tiny fat particles and the swelling solution, removing the swelling solution, washing the tiny fat particles with normal saline for 3 times, and removing blood cells;
(5) subpackaging the tiny particle fat in a 20mL injector, centrifuging at 3000rpm/min for 3min, obviously layering the fat and the water, and removing the water;
(6) subpackaging the tiny particle fat in a 20mL syringe, connecting with a nano fat converter, continuously and mechanically cutting for 10-20 times, mechanically emulsifying, and continuously oscillating the emulsified fat for 1min under the condition of artificial negative pressure;
(7) centrifuging at 3000rpm/min for 3min to obviously separate emulsified fat from oil, pouring off oil, sucking residual oil with gauze, and collecting emulsified fat;
(8) filtering emulsified fat with 0.5mm filter screen for 3 times to remove residual connective tissue to obtain fat emulsion as nanometer fat;
preparation of PRF:
(1) collecting 10 mL/10 venous blood of a patient, and putting the collected blood into a centrifuge tube without anticoagulant;
(2) centrifuging at 1400rpm/min for 20min to divide blood into three layers, including upper layer of platelet-poor plasma layer, middle layer of RPF gel layer, and lowest layer of erythrocyte layer;
(3) storing the centrifuge tube in a refrigerator at 4 deg.C for 30min, discarding the supernatant, and sucking the intermediate layer with a sterile straw to obtain PRF;
3. preparing a nano-fat combined platelet-rich fibrin composite membrane:
s1, uniformly mixing 5mL of autologous nano fat with 1mL of PRF according to a proportion, and placing at 4 ℃ for later use;
s2, stirring 5mL of QCS (mass fraction: 3%), 3mL of tannic acid (mass fraction: 2%) and 400 mu L of medical CaCl2 at normal temperature to form a uniform mixed solution;
s3, stirring the mixture of the mixture obtained in the step S1 and S2 at 4 ℃, transferring the mixture to a culture dish, and standing to form a film.
Example 3
1. Preparing autologous nano fat:
(1) local swelling anesthesia is carried out around the navel of the abdomen of the patient;
(2) after local anesthesia takes effect, a liposuction needle with the aperture of 1mm is connected with a 20mL syringe for standby;
(3) performing radial suction under the condition of artificial negative pressure to obtain about 100mL of tiny particle fat;
(4) standing the injector for 15min, obviously layering the tiny fat particles and the swelling solution, removing the swelling solution, washing the tiny fat particles with normal saline for 3 times, and removing blood cells;
(5) subpackaging the tiny particle fat in a 20mL injector, centrifuging at the rotating speed of 2500rpm/min for 3min, obviously layering the fat and the water, and removing the water;
(6) subpackaging the tiny particle fat in a 20mL syringe, connecting with a nano fat converter, continuously and mechanically cutting for 10-20 times, mechanically emulsifying, and continuously oscillating the emulsified fat for 1min under the condition of artificial negative pressure;
(7) centrifuging at 2500rpm/min for 3min to obviously separate emulsified fat from oil, pouring off oil, sucking residual oil with gauze, and collecting emulsified fat;
(8) filtering emulsified fat with 0.5mm filter screen for 3 times to remove residual connective tissue to obtain fat emulsion as nanometer fat;
preparation of PRF:
(1) collecting 10 mL/10 venous blood of a patient, and putting the collected blood into a centrifuge tube without anticoagulant;
(2) immediately centrifuging at 1400rpm/min for 20min to divide the blood into three layers, wherein the upper layer is a platelet poor plasma layer, the middle layer is an RPF gel layer, and the lowest layer is a red blood cell layer;
(3) storing the centrifuge tube in a refrigerator at 4 deg.C for 30min, discarding the supernatant, and sucking the intermediate layer with a sterile straw to obtain PRF;
3. preparing a nano-fat combined platelet-rich fibrin composite membrane:
s1, uniformly mixing 10mL of autologous nano fat with 2mL of PRF according to a proportion, and placing at 4 ℃ for later use;
s2, stirring 10mL of QCS (mass fraction: 3%), 6mL of tannic acid (mass fraction: 2%) and 800 mu L of medical CaCl2 at normal temperature to form a uniform mixed solution;
s3, stirring the mixture obtained in the step S1 and the mixed solution of S2 uniformly at 4 ℃, transferring the mixture to a culture dish, and standing to form a membrane.
Example 4
1. Preparing autologous nano fat:
(1) local swelling anesthesia is carried out around the navel of the abdomen of the patient;
(2) after local anesthesia takes effect, a liposuction needle with the aperture of 1mm is connected with a 20mL syringe for standby;
(3) performing radial suction under the condition of artificial negative pressure to obtain about 100mL of tiny particle fat;
(4) standing the injector for 15min, obviously layering the tiny fat particles and the swelling solution, removing the swelling solution, washing the tiny fat particles with normal saline for 3 times, and removing blood cells;
(5) subpackaging the tiny particle fat in a 20mL injector, centrifuging at the rotating speed of 2500rpm/min for 3min, obviously layering the fat and the water, and removing the water;
(6) subpackaging the tiny particle fat in a 20mL syringe, connecting with a nano fat converter, continuously and mechanically cutting for 10-20 times, mechanically emulsifying, and continuously oscillating the emulsified fat for 1min under the condition of artificial negative pressure;
(7) centrifuging at 2500rpm/min for 3min to obviously separate emulsified fat from oil, pouring off oil, sucking residual oil with gauze, and collecting emulsified fat;
(8) filtering emulsified fat with 0.5mm filter screen for 3 times to remove residual connective tissue to obtain fat emulsion as nanometer fat;
preparation of PRF:
(1) collecting 10 mL/10 venous blood of a patient, and putting the collected blood into a centrifuge tube without anticoagulant;
(2) centrifuging at 1500rpm/min for 14min to divide blood into three layers, including platelet-poor plasma layer in the upper layer, RPF gel layer in the middle layer, and erythrocyte layer in the lowest layer;
(3) placing the centrifuge tube in a refrigerator at 4 deg.C for 30min, discarding the supernatant, and sucking the middle layer with a sterile straw to obtain PRF;
3. preparing a nano-fat combined platelet-rich fibrin composite membrane:
s1, uniformly mixing 5mL of autologous nano fat with 1mL of PRF according to a proportion, and placing at 4 ℃ for later use;
s2, stirring 5mL of QCS (mass fraction: 4%), 3mL of resveratrol (mass fraction: 2%) and 400 mu L of medical CaCl2 to form a uniform mixed solution at normal temperature;
s3, stirring the mixture obtained in the step S1 and the mixed solution of S2 uniformly at 4 ℃, transferring the mixture to a culture dish, and standing to form a membrane.
Comparative example 1
In comparison with example 1, no autologous nano-fat was added to comparative example 1.
Preparation of PRF:
(1) collecting 10 mL/10 venous blood of a patient, and placing the collected blood into a centrifuge tube without anticoagulant;
(2) centrifuging at 1500rpm/min for 14min to divide blood into three layers, including platelet-poor plasma layer in the upper layer, RPF gel layer in the middle layer, and erythrocyte layer in the lowest layer;
(3) storing the centrifuge tube in a refrigerator at 4 deg.C for 30min, discarding the supernatant, and sucking the intermediate layer with a sterile straw to obtain PRF;
2. preparing a platelet-rich fibrin composite membrane:
s1, extracting 1mL of PRF, and placing at 4 ℃ for later use;
s2, stirring 5mL of QCS (mass fraction: 4%), 3mL of tannic acid (mass fraction: 2%) and 400 mu L of medical CaCl2 to form a uniform mixed solution at normal temperature;
s3, stirring the mixture obtained in the step S1 and the mixed solution of S2 uniformly at 4 ℃, transferring the mixture to a culture dish, and standing to form a membrane.
Comparative example 2
In comparison with example 1, no QCS and no antioxidant were added in comparative example 2.
1. Preparing autologous nano fat:
(1) local swelling anesthesia is carried out around the navel of the abdomen of the patient;
(2) after local anesthesia takes effect, a liposuction needle with the aperture of 1mm is connected with a 20mL syringe for standby;
(3) performing radial suction under the condition of artificial negative pressure to obtain about 100mL of tiny particle fat;
(4) standing the injector for 15min, obviously layering the tiny fat particles and the swelling solution, removing the swelling solution, washing the tiny fat particles with normal saline for 3 times, and removing blood cells;
(5) subpackaging the tiny particle fat in a 20mL injector, centrifuging at the rotating speed of 2500rpm/min for 3min, obviously layering the fat and the water, and removing the water;
(6) subpackaging the tiny particle fat in a 20mL syringe, connecting with a nano fat converter, continuously and mechanically cutting for 10-20 times, mechanically emulsifying, and continuously oscillating the emulsified fat for 1min under the condition of artificial negative pressure;
(7) centrifuging at 2500rpm/min for 3min to obviously separate emulsified fat from oil, pouring off oil, sucking residual oil with gauze, and collecting emulsified fat;
(8) filtering emulsified fat with 0.5mm filter screen for 3 times to remove residual connective tissue to obtain fat emulsion as nanometer fat;
preparation of PRF:
(1) collecting 10 mL/10 venous blood of a patient, and putting the collected blood into a centrifuge tube without anticoagulant;
(2) centrifuging at 1500rpm/min for 14min to divide blood into three layers, including platelet-poor plasma layer in the upper layer, RPF gel layer in the middle layer, and erythrocyte layer in the lowest layer;
(3) storing the centrifuge tube in a refrigerator at 4 deg.C for 30min, discarding the supernatant, and sucking the intermediate layer with a sterile straw to obtain PRF;
3. preparing a platelet-rich fibrin composite membrane:
s1, uniformly mixing 5mL of autologous nano fat with 1mL of PRF according to a proportion, and placing at 4 ℃ for later use;
s2, stirring uniformly 400 mu L of medical CaCl2 and S1 mixed solution at 4 ℃, transferring the mixed solution into a culture dish, and standing to form a film.
Compared with comparative examples 1 and 2, the composite membrane prepared by the example 1 has better mechanical property, antibacterial and anti-inflammatory capability and active oxygen scavenging capability than those of the comparative examples 1 and 2, and is more suitable for being used on the wound surface of the diabetic foot.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (8)
1. The platelet-rich fibrin composite membrane is characterized by being a nano-fat and platelet-rich fibrin composite membrane combined, and the nano-fat and platelet-rich fibrin composite membrane is prepared from autologous nano-fat, platelet-rich fibrin, quaternized chitosan and medical CaCl 2 The solution and the antioxidant are prepared by ion crosslinking;
the volume ratio of the formula raw materials of the nano-fat and platelet-rich fibrin composite membrane is as follows: the volume ratio of the platelet-rich fibrin to the autologous nano fat is 1: 5-1: 3, the volume ratio of the platelet-rich fibrin to the quaternized chitosan is 1: 5-1: 1, the volume ratio of the platelet-rich fibrin to the antioxidant is 1: 3-1: 1, and medical CaCl is added into each milliliter of the platelet-rich fibrin 2 The amount of the solution is 200-500. mu.L/mL.
2. The platelet-rich fibrin composite membrane according to claim 1, wherein the mass fraction of the quaternized chitosan is 2-6%.
3. The platelet-rich fibrin composite membrane according to claim 1, wherein the antioxidant is one or a mixture of two or more selected from gallic acid, tannic acid, theaflavin, dopamine, resveratrol, sodium phytate, and vitamin C.
4. The platelet-rich fibrin composite membrane according to claim 3, wherein the antioxidant is present in an amount of 1 to 4% by weight.
5. The preparation method of the platelet-rich fibrin composite membrane according to any one of claims 1 to 4, which comprises the following steps:
s1, mixing the autologous nano fat and the platelet-rich fibrin uniformly according to the volume ratio of the raw materials of the formula, and placing the mixture at 4 ℃ for later use;
s2, quaternizing the chitosan, the antioxidant and the medical CaCl under the normal temperature condition 2 The solution is stirred in proportion to form uniform mixed solution;
s3, stirring the mixture obtained in the step S1 and the mixed solution obtained in the step S2 uniformly at 4 ℃, transferring the mixture to a culture dish, and standing to form a membrane.
6. The method for preparing the platelet-rich fibrin composite membrane according to claim 5, wherein the method for preparing autologous nano-fat in step S1 is as follows:
(1) performing local swelling anesthesia around the navel of the abdomen of a patient, connecting a 20mL syringe with a liposuction needle with the aperture of 1mm, and performing radial suction under the condition of artificial negative pressure to obtain about 100mL of tiny granular fat;
(2) standing the injector for 10-15min, obviously layering the tiny fat particles and the swelling solution, removing the swelling solution, and washing the tiny fat particles with normal saline for 2-3 times;
(3) distributing the tiny particle fat in the step (2) into a 20mL injector, centrifuging for 3min at the rotating speed of 2000-3000rpm/min, removing water, and collecting the tiny particle fat;
(4) subpackaging the micro-particle fat collected in the step (3) in a 20mL syringe, connecting with a nano fat converter, continuously and mechanically cutting for 10-20 times, mechanically emulsifying, and continuously oscillating the emulsified fat for 1-2min under the condition of artificial negative pressure;
(5) centrifuging at the rotating speed of 2000-;
(6) filtering the emulsified fat with a filter screen with pore diameter of 0.5mm for 2-3 times, and removing the residual connective tissue to obtain fat emulsion, namely the autologous nano fat.
7. The method of claim 6, wherein the platelet-rich fibrin composite membrane is prepared in step S1 by the following steps:
(1) collecting 100mL of venous blood of a patient, and putting the collected blood into a centrifuge tube without anticoagulant;
(2) immediately centrifuging at the rotating speed of 1000-1600 rpm/min for 10-20min, and taking the middle gel layer to obtain platelet-rich fibrin;
(3) and storing the obtained platelet-rich fibrin at 4 ℃.
8. The application of the platelet-rich fibrin composite membrane according to any one of claims 1 to 7, in particular to the application of the platelet-rich fibrin composite membrane in diabetic foot wounds, dental tissue regeneration membranes and artificial skin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210773569.6A CN115068685A (en) | 2022-07-01 | 2022-07-01 | Platelet-rich fibrin composite membrane and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210773569.6A CN115068685A (en) | 2022-07-01 | 2022-07-01 | Platelet-rich fibrin composite membrane and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115068685A true CN115068685A (en) | 2022-09-20 |
Family
ID=83258471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210773569.6A Pending CN115068685A (en) | 2022-07-01 | 2022-07-01 | Platelet-rich fibrin composite membrane and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115068685A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813957A (en) * | 2012-09-14 | 2012-12-12 | 上海白衣缘生物工程有限公司 | Biological membrane which promotes healing and preparation method thereof |
| CN105536029A (en) * | 2015-12-25 | 2016-05-04 | 蓝广芊 | Preparation method for chitosan porous hemostatic sponge |
| WO2016164903A1 (en) * | 2015-04-10 | 2016-10-13 | Hemcon Medical Technologies, Inc. | Bioadhesive chitosan gel for controlling bleeding and for promoting healing with scar reduction without obscuring or interfering with access to a surgical field |
| CN107252502A (en) * | 2017-06-01 | 2017-10-17 | 黎洪棉 | A kind of preparation method based on nanometer adipose stromal cells reparative regeneration injected material |
| WO2018212758A1 (en) * | 2017-05-15 | 2018-11-22 | Miron Richard J | Liquid platelet-rich fibrin as a carrier system for biomaterials and biomolecules |
| CN114569704A (en) * | 2022-02-17 | 2022-06-03 | 成都清科生物科技有限公司 | Adipose-derived stem cell-loaded autologous platelet-rich fibrin gel and preparation method and application thereof |
-
2022
- 2022-07-01 CN CN202210773569.6A patent/CN115068685A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813957A (en) * | 2012-09-14 | 2012-12-12 | 上海白衣缘生物工程有限公司 | Biological membrane which promotes healing and preparation method thereof |
| WO2016164903A1 (en) * | 2015-04-10 | 2016-10-13 | Hemcon Medical Technologies, Inc. | Bioadhesive chitosan gel for controlling bleeding and for promoting healing with scar reduction without obscuring or interfering with access to a surgical field |
| CN105536029A (en) * | 2015-12-25 | 2016-05-04 | 蓝广芊 | Preparation method for chitosan porous hemostatic sponge |
| WO2018212758A1 (en) * | 2017-05-15 | 2018-11-22 | Miron Richard J | Liquid platelet-rich fibrin as a carrier system for biomaterials and biomolecules |
| CN107252502A (en) * | 2017-06-01 | 2017-10-17 | 黎洪棉 | A kind of preparation method based on nanometer adipose stromal cells reparative regeneration injected material |
| CN114569704A (en) * | 2022-02-17 | 2022-06-03 | 成都清科生物科技有限公司 | Adipose-derived stem cell-loaded autologous platelet-rich fibrin gel and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 陆树良主编: "《脂肪整形必须知道的99个问题》", 上海科学技术出版社, pages: 197 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101991875B (en) | Mesoporous bioactive glass and chitosan composite porous hemostatic material and preparation method thereof | |
| CN104758977B (en) | A kind of alginate dressing for treating bedsore and preparation method thereof | |
| WO2016004212A1 (en) | Hydrogels for treating and ameliorating wounds and methods for making and using them | |
| CN101804218A (en) | Human-body absorbable trauma dressing containing Yunnan white drug powder or Yunnan white drug powder extractive | |
| CN107206133A (en) | Platelet rich plasma for preparing individually or combining hyaluronic acid（PRP）Or marrow centrate（BMC）New standard and medicine equipment | |
| CN110664735A (en) | Platelet-rich gel and preparation method thereof | |
| CN104069537A (en) | Sodium alginate-sodium carboxymethylcellulose-chitosan wound dressing and preparation method thereof | |
| Jameson | Autologous platelet concentrate for the production of platelet gel | |
| CN113058070B (en) | Rapid hemostatic dressing and preparation method thereof | |
| CN107496972B (en) | Anti-adhesion wet dressing for promoting healing of burn wound and preparation method thereof | |
| CN108478846A (en) | A kind of medical hemostatic antiseptic dressing and preparation method thereof | |
| Khorasani et al. | The effects of Aloe Vera cream on split-thickness skin graft donor site management: a randomized, blinded, placebo-controlled study | |
| CN101569761A (en) | Preparation method for medical honey dressing | |
| US20230201314A1 (en) | Use of advanced platelet-rich fibrin in preparing medicament for treatment of diabetic foot ulcer | |
| JP2009235004A (en) | Method for promoting cellular tissue increase and method for ameliorating skin problem, and kit used in these methods | |
| CN115089755A (en) | Medical dressing composition of recombined fibronectin-humanized collagen with repairing effect and preparation method thereof | |
| CN113274410A (en) | Application of exosome hydrogel complex in preparation of medicine for repairing skin scar | |
| CN115068685A (en) | Platelet-rich fibrin composite membrane and preparation method and application thereof | |
| RU2543344C2 (en) | Method of treating trophic ulcers | |
| CN103536957A (en) | Novel collagen-beta-cyclodextrin controlled-release dressing and preparation method thereof | |
| RU2657806C2 (en) | Method for regional treatment of trophic ulcers | |
| CN115501385A (en) | Wound film-forming dressing for promoting wound healing and preparation method thereof | |
| CN114748670A (en) | Non-woven hemostatic gauze and preparation method and application thereof | |
| El Nagar et al. | Comparative study between negative pressure wound therapy and platelet rich plasma in neovascularization of chronic wound healing | |
| King | Catrix: an easy-to-use collagen treatment for wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220920 |